Press release
Esophageal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in Esophageal Cancer Research. Learn more about our innovative pipeline today! @ Esophageal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Esophageal Cancer Pipeline Report
* In February 2025:- Hoffmann-La Roche:- The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo plus PC as first-line treatment in participants with unresectable locally advanced, unresectable recurrent, or metastatic esophageal carcinoma (EC).
* In February 2025:- Shanghai Henlius Biotech:- The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or Intolerance to Standard First-Line Therapy.
* In February 2025:- AstraZeneca :- This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
* In February 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
* In February 2025:- Janssen Research & Development LLC:- The primary purpose of this study is to evaluate objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of erdafitinib in a molecularly-defined subset of Asian participants with non-small-cell lung cancer (NSCLC), urothelial cancer, esophageal cancer and cholangiocarcinoma.
* DelveInsight's Esophageal Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Esophageal Cancer treatment.
* The leading Esophageal Cancer Companies such as BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc ., and others.
* Promising Esophageal Cancer Therapies such as Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.
Stay informed about the cutting-edge advancements in Esophageal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Esophageal Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Cancer Emerging Drugs Profile
* AN-0025: Adlai Nortye
AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer.
* Tucatinib: Seagen
Tucatinib (TUKYSA Registered ) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer.
* APX 005M: Apexigen
APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.
The Esophageal Cancer pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
* Esophageal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.
Get a detailed analysis of the latest innovations in the Esophageal Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Esophageal Cancer Unmet Needs [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Cancer Therapeutics Assessment
There are approx. 80+ key Esophageal Cancer companies which are developing the therapies for Esophageal Cancer. The Esophageal Cancer companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. phase II/III include, Seagen.
Esophageal Cancer Companies
BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.
Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Esophageal Cancer Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming Esophageal Cancer Therapies and key Esophageal Cancer Developments @ Esophageal Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Esophageal Cancer Pipeline Report
* Coverage- Global
* Esophageal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Esophageal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc ., and others.
* Esophageal Cancer Therapies- Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.
Which companies are leading the race in Esophageal Cancer drug development? Find out in DelveInsight's exclusive Esophageal Cancer Pipeline Report-access it now! @ Esophageal Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Esophageal Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Esophageal Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Last Stage Products (Phase II/III)
* Tucatinib: Seagen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* APX 005M: Apexigen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Esophageal Cancer Key Companies
* Esophageal Cancer Key Products
* Esophageal Cancer - Unmet Needs
* Esophageal Cancer - Market Drivers and Barriers
* Esophageal Cancer - Future Perspectives and Conclusion
* Esophageal Cancer Analyst Views
* Esophageal Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Esophageal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3884127 • Views: …
More Releases from ABNewswire
Stop Settling for Tiny Freezers: Get the 3-Door Powerhouse Built for Sales
Hey Store Managers! We know running a busy frozen food section means constantly fighting two battles: keeping enough stock on the floor and making sure those products look tempting enough to jump into the cart. When you're dealing with high-volume frozen goods, those small freezers just don't cut it.
That's why we're excited to talk about our specialized 3-Door Freezer [https://www.runtecool.com/glass-door-upright-chiller/] unit, engineered specifically for the demands of the modern supermarket.…
2025 Recap: Waterproof Bedding Innovations - Industry Trends and Best Practices
Introduction: How 2025 Redefined Waterproof Bedding
The year 2025 unfolded as a transformative chapter for the waterproof bedding [https://www.meihumaterial.com/products/] industry. Innovations accelerated, materials evolved, and consumer expectations rose sharply. What once felt like a simple protective accessory matured into a category defined by comfort, intelligence, sustainability, and design finesse. Waterproof bedding was no longer just a shield-it became a vital component of modern sleep culture.
This surge in advancement was driven by…
How Providing Comprehensive Drawing Details Accelerates OEM Seal Quotes & Protot …
For OEM engineers and procurement specialists, navigating the custom sealing component journey-from initial quote to physical prototype-can be a race against the clock. At King Rubber Products Inc. [https://www.king-rubber.com/], we understand that time is a critical resource in your product development cycle. A common bottleneck in this process is incomplete or ambiguous drawing information. By partnering with us and providing a specific set of drawing details upfront, you can significantly…
Yuchai YCK08-60 vs YCK09-60: Deep Technical Comparison with Global Heavy-Duty En …
In today's global heavy-duty engine market, competition has evolved beyond raw horsepower to encompass efficiency, emissions, and lifecycle reliability. As a leading Chinese manufacturer, Yuchai Group continues to set benchmarks in engine innovation.
Among its newest generation of China VI-compliant engines, the YCK08-60 [https://www.nzhengine.com/yuchai-yck09-60-diesel-engine-400hp-1700n-m-china-vi-dump-trucks-product/] and YCK09-60 [https://www.nzhengine.com/yuchai-yck08-60-8l-diesel-engine-350-hp-china-vi-euro-vi-level-excellent-fuel-economy-product/] stand out as flagship models designed for trucks, buses, and construction machinery.This article provides an in-depth, factual comparison between these two engines and benchmarks…
More Releases for Esophageal
Rising Prevalence Of Chronic Esophageal Disorders Boosts The Esophageal Catheter …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Esophageal Catheters Market Size By 2025?
The market for esophageal catheters has experienced significant expansion recently. Its growth is projected to continue from a market size of $2.43 billion in 2024 to an increased value of $2.64 billion in 2025, reflecting a compound annual growth…
Evolving Market Trends In The Esophageal Dilator Industry: Advanced Solutions En …
The Esophageal Dilator Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Esophageal Dilator Market Size During the Forecast Period?
The esophageal dilator market size will grow from $1.49 billion in 2024 to $1.57 billion in 2025 at a CAGR of 5.2%. Growth…
Evolving Market Trends In The Esophageal Dysphagia Industry: Innovative Technolo …
The Esophageal Dysphagia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Esophageal Dysphagia Market Size During the Forecast Period?
The market size for esophageal dysphagia has seen robust growth in the past few years. Projections show that it is set to expand…
Key Trend Reshaping the Esophageal Dilator Market in 2025: Advanced Solutions En …
What combination of drivers is leading to accelerated growth in the esophageal dilator market?
The esophageal dilator market is expected to see growth driven by the increasing occurrence of esophageal disorders. These disorders refer to a range of conditions affecting the esophagus, responsible for transporting food and fluids from the mouth to the stomach. The escalated prevalence of such disorders can be linked to factors such as the growing instances of…
Advanced Solutions Enhanced Esophageal Dilator Market Trend: A Crucial Influence …
What Is the Expected Size and Growth Rate of the Esophageal Dilator Market?
The market size for esophageal dilators has experienced robust growth in the past few years. The market's value, estimated at $1.49 billion in 2024, is predicted to inflate to $1.57 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.2%. This positive trend during the historical period is primarily driven by factors such as an increase…
Top Factor Driving Esophageal Catheters Market Growth in 2025: Rising Prevalence …
How Big Is the Esophageal Catheters Market Expected to Be, and What Will Its Growth Rate Be?
The esophageal catheters market has experienced significant growth in recent years. It will grow from $2.43 billion in 2024 to $2.64 billion in 2025, at a CAGR of 8.6%. The growth can be attributed to advancements in critical care, the rise of cardiac and respiratory disorders, the use of minimally invasive procedures, and developments…
